In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Acute myeloid leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer. This study explores the role of ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the existence of gene mutations based on images of leukemia cells.

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of ...

Caribou Biosciences (CRBU) reported better-than-expected earnings in the first quarter, with top and bottom-line beats.

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in ...

Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...